Navigation Links
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Date:1/18/2008

[p<0.0001].

-- Significantly greater mean increase in CD4+ cell count from baseline;

mean increase of 81 vs. 64 cells/mm(3)[p=0.0022]

The results of DUET-1 and DUET-2 were published separately in two articles in the July 7, 2007 issue of The Lancet, and the pooled analysis from the DUET studies was presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in September 2007.

DUET-1 and -2 Resistance

-- The presence of K103N, which was the most prevalent NNRTI substitution

in DUET-1 and -2 studies at baseline, did not affect the response in

the INTELENCE arm.

-- The presence at baseline of the substitutions V179D, V179F, V179T,

Y181V, or G190S was associated with a decreased virologic response to

INTELENCE.

-- In the DUET-1 and -2 studies, the presence at baseline of three or more

2007 IAS-USA-defined NNRTI substitutions (V90I, A98G, L100I, K101E/P,

K103N, V106A/I/M, V108I, V179D/F, Y181C/I/V, Y188C/H/L, G190A/S, P225H)

resulted in a decreased virologic response to INTELENCE.

-- For patients in the DUET-1 and -2 studies experiencing virologic

failure on an INTELENCE-containing regimen, the substitutions that

occurred most commonly were V179F, V179I, Y181C, and Y181I which

usually emerged in a background of multiple other NNRTI

resistance-associated substitutions. Other NNRTI resistance-associated

substitutions which emerged in patients on INTELENCE treatment in

< 10 percent of the virologic failure isolates included K101E, K103N,

V106I/M, V108I, Y188L, V189I, G190S/C and R356K.

-- Cross-resistance to delavirdine, efavirenz, and/or nevirapine is

expected after virologic failure with an INTELENCE-containing regimen.

DUET-1 and -2 Tolerability

In the DUET-1 and -2 studies, the most common adverse events (> 10 percent) o
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
2. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
3. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
5. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
6. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
7. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
10. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
11. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Genedata, a leading provider of advanced ... research, today announced the release of Genedata ... enterprise solution for biologics R&D. This first-in-class workflow ... and development of novel biotherapeutics. Version 5.0 enables ... optimization and developability requirements. Genedata will present highlights ...
(Date:5/4/2015)... 4, 2015 China Cord Blood Corporation (NYSE: ... China,s leading provider of cord blood collection, ... storage services, today announced that the Company has been ... Hong Kong listed company and ... an agreement (the "Agreement") to purchase the Company,s outstanding ...
(Date:5/4/2015)... 2015   Intrexon Corporation (NYSE: XON ... financial results after the market closes on May 11, ... day at 5:30 PM ET to discuss the results ... conference call may be accessed by dialing 1-888-346-3959 (Domestic ... "Intrexon Conference Call."  Participants may also access the live ...
(Date:5/1/2015)... , May 1, 2015  Northwest Biotherapeutics (NASDAQ: ... DCVax® personalized immune therapies for solid tumor cancers, announced ... million second tranche of a $40 million investment from ... Woodford first invested $25 million in NW Bio on ... into an agreement with the Company for a further ...
Breaking Biology Technology:Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3
... , LONDON, September 8, 2008 / ... certainly does not seem to have hit the European ... registered attendees as in past years, eyeforpharma’s upcoming Marketing ... to be the biggest event of its kind ever. ...
... Joseph F. Finn, Jr.,C.P.A. ("Finn"), Assignee of ... benefit of creditors, announced today that all ... at a sealed bid auction on October ... thermoplastic,polymers, Spheromers(TM), have superior conventional hydrophilic,bioadhesive polymers. ...
... Sept. 9 ( http://www.amdl.com ),AMDL, Inc. (Amex: ... operations in China and the US, today announced that ... with Mr.,Gary Dreher, President and CEO of AMDL, Inc., ... copy of the interview is available in the,Healthcare Services ...
Cached Biology Technology:Eyeforpharma's Marketing Summit is shaping up to be the biggest event of its kind ever 2Spherics, Inc. Announces Sale of Novel Proprietary Bioadhesive Polymers and Oral Drug Delivery System 2The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue 2
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... triggered a similar marine ecosystem crisis to those witnessed ... according to research published today in Nature Geoscience ... of Newcastle, UK, Cologne, Frankfurt and GEOMAR-Kiel, confirms the ... marine ecosystem during the mid-Cretaceous greenhouse period. ...
... aren,t the only ones tending their gardens. At ... leaf-cutter ants cultivate thriving communities of fungi and bacteria ... gardens are a source of food and shelter for ... better biofuel production. "We are interested in the ...
... World War II soldiers, "The White Cliffs of Dover" was ... geographers, the white cliffs mark the point at which England ... are towering structures made of the chalky, white shells that ... . "Ehux" is a coccolithophore, with an exoskeleton made of ...
Cached Biology News:Global cooling as significant as global warming 2Researchers unearth bioenergy potential in leaf-cutter ant communities 2Researchers unearth bioenergy potential in leaf-cutter ant communities 3Chalking up a marine blooming alga: Genome fills a gap in the tree of life 2Chalking up a marine blooming alga: Genome fills a gap in the tree of life 3Chalking up a marine blooming alga: Genome fills a gap in the tree of life 4
Melanoma Antigen, Family C, 1 (MAGEC1) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: New Recommended Storage: Long term: -20C; Short term: +4...
...
ECE-1 (H-60)...
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
Biology Products: